CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade NeuroBo Pharmaceuticals, Inc. - NRBO CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Neurobo Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 0.36-63.85
Average Volume (10 days) 132.33K
Average Volume (3 months) 8.10M
Market Cap 17.60M
P/E Ratio -100.00K
Shares Outstanding 38.43M
Revenue N/A
EPS -4.23
Dividend (Yield %) N/A
Beta 0.02
Next Earnings Date Nov 13, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low

NeuroBo Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Monday, November 13, 2023

Time (UTC)

21:00

Country

US

Event

Q3 2023 Neurobo Pharmaceuticals Inc Earnings Release
Q3 2023 Neurobo Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 19.628 15.298 29.716 21.29 22.805
Selling/General/Admin. Expenses, Total 8.64 8.752 7.846 2.701 8.493
Research & Development 2.778 6.546 4.531 5.324 14.312
Unusual Expense (Income) 8.21 0 17.339 13.265
Operating Income -19.628 -15.298 -29.716 -21.29 -22.805
Interest Income (Expense), Net Non-Operating -2.191 0.014 0.039 -0.022 -0.654
Other, Net 7.852 0 -0.001 0 -0.178
Net Income Before Taxes -13.967 -15.284 -29.678 -21.312 -23.637
Net Income After Taxes -13.967 -15.284 -29.678 -21.312 -23.637
Net Income Before Extra. Items -13.967 -15.284 -29.678 -21.312 -23.637
Net Income -13.967 -15.284 -29.678 -21.312 -23.637
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -13.967 -15.284 -29.678 -21.312 -23.637
Income Available to Common Incl. Extra. Items -13.967 -15.284 -29.678 -21.312 -23.637
Diluted Net Income -13.967 -15.284 -29.678 -21.312 -23.637
Diluted Weighted Average Shares 2.57362 0.77138 0.54052 0.17412 0.01841
Diluted EPS Excluding Extraordinary Items -5.42698 -19.8138 -54.906 -122.397 -1284.23
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.23692 -19.8138 -22.8279 -46.2148 -1284.23
Total Extraordinary Items
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 3.806 2.52 10.43 3.104 3.219
Selling/General/Admin. Expenses, Total 1.442 1.883 1.915 2.533 2.237
Research & Development 2.364 0.637 0.305 0.571 0.982
Operating Income -3.806 -2.52 -10.43 -3.104 -3.219
Interest Income (Expense), Net Non-Operating -2.191 0 0
Other, Net 3.072 -0.084 7.945 -0.009 -0.084
Net Income Before Taxes -0.734 -2.604 -4.676 -3.113 -3.303
Net Income After Taxes -0.734 -2.604 -4.676 -3.113 -3.303
Net Income Before Extra. Items -0.734 -2.604 -4.676 -3.113 -3.303
Net Income -0.734 -2.604 -4.676 -3.113 -3.303
Income Available to Common Excl. Extra. Items -0.734 -2.604 -4.676 -3.113 -3.303
Income Available to Common Incl. Extra. Items -0.734 -2.604 -4.676 -3.113 -3.303
Diluted Net Income -0.734 -2.604 -4.676 -3.113 -3.303
Diluted Weighted Average Shares 40.472 27.1767 7.62842 0.88869 0.88873
Diluted EPS Excluding Extraordinary Items -0.01814 -0.09582 -0.61297 -3.5029 -3.71656
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.01814 -0.09582 0.46327 -3.5029 -3.71656
Unusual Expense (Income) 8.21
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 33.532 16.584 10.683 14.118 19.686
Cash and Short Term Investments 33.364 16.387 10.089 13.908 18.954
Cash & Equivalents 33.364 16.387 10.089 13.908 18.954
Prepaid Expenses 0.168 0.197 0.546 0.153 0.715
Total Assets 33.534 16.799 10.968 14.468 19.694
Other Long Term Assets, Total 0.008
Total Current Liabilities 11.784 2.157 3.695 2.082 11.919
Accounts Payable 0.708 0.83 2.575 0.638 2.044
Accrued Expenses 0.28 1.327 1.12 1.444 0.438
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 10.796
Total Liabilities 11.784 2.202 3.765 2.176 11.92
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0 0.045 0.07 0.094 0.001
Total Equity 21.75 14.597 7.203 12.292 7.774
Common Stock 0.025 0.027 0.02 0.016 0.022
Additional Paid-In Capital 117.52 96.394 73.713 49.13 91.863
Retained Earnings (Accumulated Deficit) -95.795 -81.828 -66.544 -36.866 -84.111
Total Liabilities & Shareholders’ Equity 33.534 16.799 10.968 14.468 19.694
Total Common Shares Outstanding 25.436 0.88864 0.65564 0.51971 0.01902
Other Current Assets, Total 0 0.048 0.057 0.017
Current Port. of LT Debt/Capital Leases 9.437
Long Term Debt 0 0
Property/Plant/Equipment, Total - Net 0.002 0.215 0.285 0.35
Property/Plant/Equipment, Total - Gross 0.03 0.326 0.348 0.367
Accumulated Depreciation, Total -0.028 -0.111 -0.063 -0.017
Other Equity, Total 0 0.004 0.014 0.012
Preferred Stock - Non Redeemable, Net 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 31.483 33.532 7.554 10.077 13.264
Cash and Short Term Investments 30.813 33.364 6.356 8.849 11.557
Cash & Equivalents 30.813 33.364 6.356 8.849 11.557
Prepaid Expenses 0.67 0.168 0.859 1.228 1.707
Other Current Assets, Total 0.339
Total Assets 31.488 33.534 7.557 10.082 13.461
Property/Plant/Equipment, Total - Net 0.005 0.002 0.003 0.005 0.197
Property/Plant/Equipment, Total - Gross 0.034 0.03 0.03 0.03 0.32
Accumulated Depreciation, Total -0.029 -0.028 -0.027 -0.025 -0.123
Total Current Liabilities 10.98 11.784 1.619 1.249 1.496
Accounts Payable 1.119 0.708 1.075 0.664 0.776
Accrued Expenses 0.417 0.28 0.544 0.585 0.72
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 10.98 11.784 1.619 1.249 1.533
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0 0 0 0.037
Total Equity 20.508 21.75 5.938 8.833 11.928
Common Stock 0.027 0.025 0.001 0.027 0.027
Additional Paid-In Capital 118.88 117.52 97.056 96.812 96.601
Retained Earnings (Accumulated Deficit) -98.399 -95.795 -91.119 -88.006 -84.703
Other Equity, Total 0 0 0 0.003
Total Liabilities & Shareholders’ Equity 31.488 33.534 7.557 10.082 13.461
Total Common Shares Outstanding 27.1767 25.436 0.88869 0.88864 0.88864
Preferred Stock - Non Redeemable, Net 0 0 0 0
Other Current Liabilities, Total 9.444 10.796
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -13.967 -15.284 -29.678 -21.312 -15.529
Cash From Operating Activities -11.712 -15.134 -10.764 -7.039 -14.451
Non-Cash Items 3.403 0.686 18.059 13.512 1.856
Cash Taxes Paid 0 0 0
Cash Interest Paid 0 0.001 0
Changes in Working Capital -1.168 -0.584 0.809 0.744 -0.778
Cash From Financing Activities 28.681 22.026 6.858 24.167 17.246
Financing Cash Flow Items -3.569 -2.089 -0.695 -0.074 -0.054
Issuance (Retirement) of Stock, Net 32.25 24.115 7.553 24.241 16.8
Issuance (Retirement) of Debt, Net 0 0.5
Net Change in Cash 16.977 6.298 -3.834 11.078 2.795
Cash From Operating Activities 0.02 0.048 0.046 0.017 0
Cash From Investing Activities 0.008 -0.586 0.069 -6.057 -0.003
Capital Expenditures 0 -0.003 -0.004 -0.214 -0.003
Other Investing Cash Flow Items, Total 0.008 -0.583 0.073 -5.843 0
Foreign Exchange Effects 0 -0.008 0.003 0.007 0.003
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -2.604 -13.967 -9.291 -6.178 -2.875
Cash From Operating Activities -2.547 -11.712 -9.905 -7.546 -4.829
Cash From Operating Activities 0.001 0.02 0.019 0.017 0.012
Non-Cash Items 0.01 3.403 0.719 0.501 0.213
Cash Taxes Paid
Cash Interest Paid
Changes in Working Capital 0.046 -1.168 -1.352 -1.886 -2.179
Cash From Investing Activities -0.004 0.008 0.008 0.008 0
Capital Expenditures -0.004 0 0
Cash From Financing Activities 0 28.681 -0.134 0 0
Financing Cash Flow Items 0 -3.569 -0.134 0 0
Issuance (Retirement) of Stock, Net 32.25 0 0 0
Foreign Exchange Effects 0 0 0 0 -0.001
Net Change in Cash -2.551 16.977 -10.031 -7.538 -4.83
Other Investing Cash Flow Items, Total 0.008 0.008 0.008 0

NeuroBo Pharmaceuticals, Inc. Company profile

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.
Industry: Bio Therapeutic Drugs

200 Berkeley St.
Fl 19
BOSTON
MASSACHUSETTS 02116
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

ETH/USD

1,601.10 Price
+0.450% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

XRP/USD

0.52 Price
+0.510% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

BTC/USD

26,722.35 Price
+0.120% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Oil - Crude

90.20 Price
+0.960% 1D Chg, %
Long position overnight fee 0.0349%
Short position overnight fee -0.0568%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading